Interviste

Overall survival results from the phase III MONALEESA-2 trial of postmenopausal patients with HR+/HER2- advanced breast cancer treated with ET ± ribociclib

Stratificazione del rischio della popolazione per il BC: dall’ESMO si conferma la fine della “one size fits all”?

Primary outcome of the phase III SYD985,002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2+ locally advanced or metastatic breast cancer

Equità di genere nel BC: quale dibattito e quali prospettive per un problema sociale più che personale fra stigma, miti e tabù culturali?

Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early- stage breast cancer: A randomised, phase III trial of the Gruppo Italiano Mammella

KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC